Q-omics provides the consensus-scored PCDHGA7 profile across patient tissues and cancer cell-line models. PCDHGA7 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, PCDHGA7 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, PCDHGA7 RNA expression shows 16,984 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, KICH, and THYM as cancer lineages where PCDHGA7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCDHGA7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCDHGA7 survival associations across molecular data types. PCDHGA7 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCDHGA7 RNA expression–survival associations across cancer types. High PCDHGA7 expression shows unfavorable associations in BLCA, CESC, LUSC, STAD and BRCA, but favorable associations in MESO. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for PCDHGA7 RNA expression.
This table summarizes PCDHGA7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for PCDHGA7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCDHGA7 shows lower tumor expression in KICH, KIRP, UCEC, COAD and LUSC and higher tumor expression in CHOL. The KICH box plot shows higher PCDHGA7 RNA expression in normal versus tumor tissue (log2 FC = −0.817, t-test p < 0.001).
This table shows molecular features associated with PCDHGA7 in patient tissues and cancer cell lines. In patient samples, PCDHGA7 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PCDHGA7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
